Biotech RadarJobs updated

COMPANY

Celltex Therapeutics

celltexbank.com ↗ · Southwest

Clinical Phase 2

Profile checked Oct 10, 2026

Keywords: Alzheimer Disease Corona Virus Infection Covid19 Rheumatoid Arthritis Knee Osteoarthritis Hip Osteoarthritis Osteoarthritis Shoulder COVID-19 autologous adipose derived stem cells Adipose-Derived Mesenchymal Stem Cells Allogeneic adipose-derived stem cells Celltex- AdMSCs

5Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells source ↗
  2. Trial start Phase 1/Phase 2: Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis source ↗
  3. Trial start Phase 2: Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis source ↗
  4. Trial start Phase 2: Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 source ↗

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT04855955Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's DiseaseNot listedNo longer availableNot listedNot listed
NCT05017298Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem CellsPhase 2Not yet recruitingNov 1, 2024Nov 1, 2024 (estimated)
NCT04170426Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid ArthritisPhase 1/Phase 2Not yet recruiting2023-122024-12 (estimated)
NCT04448106Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for OsteoarthritisPhase 2Unknown status (ClinicalTrials.gov)Sep 25, 2023Aug 1, 2024 (estimated)
NCT04428801Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19Phase 2Unknown status (ClinicalTrials.gov)2023-092024-09 (estimated)
Feedback